@drlw2309 This updated meta-analysis shows OS benefit of capecitabine in TNBC in the adjuvant setting - so it can no longer be an excuse to give neoadjuvant chemotherapy; in fact the latter may deny it to patients in whom it might be beneficial. https://
RT @ajumathew_: One advantage of neoadj chemo is illustrated in this vignette from my practice. I now know she has a rather chemo resista…
One advantage of neoadj chemo is illustrated in this vignette from my practice. I now know she has a rather chemo resistant disease. @jsvaidya #bcsm What would you do in such a case?Patient can't afford T-DM1. @StoverLab @matteolambe @DrMassarweh @dar
@SirohiBhawna @oncology_bg @ajumathew_ @sujithonco @DrSanjayPopat @JyotiBajpai01 @GillSharlene @weoncologists @oncologician @OncoAlert @ShikhaJainMD @Amolpatel_dr @VanitaNoronha For breast cancer, neoadjuvant chemotherapy in patients when operable / when i
@drlw2309 CREATE-X only included post-neoadjuvant. It also excluded those who initially responded. AND this Cochrane meta-analysis shows benefit of Capecitabine in adjuvant setting for ER neg cases. https://t.co/XBvvy21Vus Another reason to rethink neoad
RT @CochraneLibrary: Benefits of capecitabine in hormone receptor‐positive compared to hormone receptor‐negative breast cancer https://t.co…
RT @CochraneLibrary: Benefits of capecitabine in hormone receptor‐positive compared to hormone receptor‐negative breast cancer https://t.co…
RT @CochraneLibrary: Benefits of capecitabine in hormone receptor‐positive compared to hormone receptor‐negative breast cancer https://t.co…
RT @CochraneLibrary: Benefits of capecitabine in hormone receptor‐positive compared to hormone receptor‐negative breast cancer https://t.co…
RT @CochraneBCancer: New review available on capecitabine in hormone receptor-positive or hormone receptor-negative breast cancer https://t…
RT @VCCLibrary: Cochrane Review: Capecitabine for hormone receptor‐positive versus hormone receptor‐negative #breastcancer https://t.co/3pk…
Benefits of capecitabine in hormone receptor‐positive compared to hormone receptor‐negative breast cancer https://t.co/2dmH6VjNzY New @CochraneBCancer systematic review looks at the evidence from 26 studies. #breastcancertreatment #BreastCancer #CancerRes
RT @DrPeterLau: Hearty congratulations to my co-authors @siaoness, Alison White, @TrishBanksOnc , Max Bulsara and Andrew Redfern for final…
Cochrane Review: Capecitabine for hormone receptor‐positive versus hormone receptor‐negative #breastcancer https://t.co/3pkieEmk7m #Cancer
RT @DrPeterLau: Hearty congratulations to my co-authors @siaoness, Alison White, @TrishBanksOnc , Max Bulsara and Andrew Redfern for final…
RT @DrPeterLau: Hearty congratulations to my co-authors @siaoness, Alison White, @TrishBanksOnc , Max Bulsara and Andrew Redfern for final…
RT @DrPeterLau: Hearty congratulations to my co-authors @siaoness, Alison White, @TrishBanksOnc , Max Bulsara and Andrew Redfern for final…
Hearty congratulations to my co-authors @siaoness, Alison White, @TrishBanksOnc , Max Bulsara and Andrew Redfern for finally publishing this Cochrane Review on Breast Cancer. https://t.co/ekgouRQVzw
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer https://t.co/Q8jcVSSkoo
New review available on capecitabine in hormone receptor-positive or hormone receptor-negative breast cancer https://t.co/gikv67keWR. Review includes evidence from 26 studies